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Summary
Background In children, SARS-CoV-2 infection is usually asymptomatic or causes a mild illness of short duration. 
Persistent illness has been reported; however, its prevalence and characteristics are unclear. We aimed to determine 
illness duration and characteristics in symptomatic UK school-aged children tested for SARS-CoV-2 using data from 
the COVID Symptom Study, one of the largest UK citizen participatory epidemiological studies to date.
Methods In this prospective cohort study, data from UK school-aged children (age 5–17 years) were reported by an 
adult proxy. Participants were voluntary, and used a mobile application (app) launched jointly by Zoe Limited and 
King’s College London. Illness duration and symptom prevalence, duration, and burden were analysed for children 
testing positive for SARS-CoV-2 for whom illness duration could be determined, and were assessed overall and for 
younger (age 5–11 years) and older (age 12–17 years) groups. Children with longer than 1 week between symptomatic 
reports on the app were excluded from analysis. Data from symptomatic children testing negative for SARS-CoV-2, 
matched 1:1 for age, gender, and week of testing, were also assessed.
Findings 258 790 children aged 5–17 years were reported by an adult proxy between March 24, 2020, and Feb 22, 2021, 
of whom 75 529 had valid test results for SARS-CoV-2. 1734 children (588 younger and 1146 older children) had a 
positive SARS-CoV-2 test result and calculable illness duration within the study timeframe (illness onset between 
Sept 1, 2021, and Jan 24, 2021). The most common symptoms were headache (1079 [62·2%] of 1734 children), and 
fatigue (954 [55·0%] of 1734 children). Median illness duration was 6 days (IQR 3–11) versus 3 days (2–7) in children 
testing negative, and was positively associated with age (Spearman’s rank-order rs 0·19, p<0·0001). Median illness 
duration was longer for older children (7 days, IQR 3–12) than younger children (5 days, 2–9). 77 (4·4%) of 
1734 children had illness duration of at least 28 days, more commonly in older than younger children (59 [5·1%] of 
1146 older children vs 18 [3·1%] of 588 younger children; p=0·046). The commonest symptoms experienced by these 
children during the first 4 weeks of illness were fatigue (65 [84·4%] of 77), headache (60 [77·9%] of 77), and anosmia 
(60 [77·9%] of 77); however, after day 28 the symptom burden was low (median 2 symptoms, IQR 1–4) compared with 
the first week of illness (median 6 symptoms, 4–8). Only 25 (1·8%) of 1379 children experienced symptoms for at 
least 56 days. Few children (15 children, 0·9%) in the negatively tested cohort had symptoms for at least 28 days; 
however, these children experienced greater symptom burden throughout their illness (9 symptoms, IQR 7·7–11·0 
vs 8, 6–9) and after day 28 (5 symptoms, IQR 1·5–6·5 vs 2, 1–4) than did children who tested positive for SARS-CoV-2.
Interpretation Although COVID-19 in children is usually of short duration with low symptom burden, some children 
with COVID-19 experience prolonged illness duration. Reassuringly, symptom burden in these children did not 
increase with time, and most recovered by day 56. Some children who tested negative for SARS-CoV-2 also had 
persistent and burdensome illness. A holistic approach for all children with persistent illness during the pandemic is 
appropriate.
Funding Zoe Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and 
Physical Sciences Research Council, UK Research and Innovation London Medical Imaging and Artificial Intelligence 
Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British 
Heart Foundation, and Alzheimer’s Society.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
SARS-CoV-2 has caused more than 190 million cases of 
COVID-19 and 4 million deaths globally, as of July 21, 2021. 
In adults, SARS-CoV-2 causes a predominantly respir atory 
illness;1,2 children are often asymptomatic (in 43–68% of 
cases) or have mild symptoms,3 and life-threatening 
illness and death from COVID-19 are rare.4,5 The pandemic 
has also resulted in the emergence of a new rare condition, 
termed multi system inflammatory syndrome in children 
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(MIS-C),6 presenting at about 2–4 weeks after acute 
SARS-CoV-2 infection.7
Some adults with COVID-19 experience prolonged 
illness duration, known as ‘‘long COVID’’.8,9 Longitudinal 
data from the King’s College London COVID Symptom 
Study10 showed that 13·3% of adults with a positive test 
for SARS-CoV-2 had symptoms for at least 4 weeks 
(referred to as LC28) and 4·5% had symptoms for at least 
8 weeks (LC56).2 Whether some children also experience 
prolonged illness duration,9,11 and if so, how this compares 
with other illnesses, is unknown.
In September, 2020, coinciding with UK schools 
re-opening, governance for COVID Symptom Study data 
usage was extended to allow analysis of data from children. 
The UK subsequently experienced further pandemic 
waves, during which testing was widely available for 
individuals experiencing fever, cough, anosmia, or a 
combin ation of these symptoms, in contrast to the 
first wave when testing was mostly restricted to indi-
viduals presenting to hospital.12,13 Stay-at-home directives 
and school closures over winter resulted in unusually low 
circulation of viruses such as influenza and adenovirus in 
the UK;14 however, individuals who contracted other 
respiratory illnesses were often tested for SARS-CoV-2 due 
to symptom overlap.
We aimed to investigate illness duration and symptom 
prevalence, duration, and burden in UK school-aged 
children (age 5–17 years) testing positive for SARS-CoV-2, 
and similar data for symptomatic children testing negative.
Methods 
Study design and participants 
This prospective cohort study analysed data acquired from 
voluntary participants in the COVID Symptom Study, 
who self-reported data through a mobile application (app) 
launched jointly by Zoe Limited and King’s College 
London on March 24, 2020, freely available to download in 
the UK (full details in appendix pp 1–2).10,15 Briefly, upon 
registration, participants provide consent for their data 
to be used in COVID-19 research, and key demographic 
and comorbidity data (eg, presence of diabetes or asthma). 
Subsequently, participating individuals are prompted to 
report daily any symptoms (with direct questions about 
specific symptoms listed in the appendix p 3, and free-
text entry), any SARS-CoV-2 tests and results, vaccination 
details, and health-care access.10 Adult contributors can 
also proxy-report for others, including children. Relation-
ships between contributor and proxy-reported individuals 
are not solicited. 
Ethics approval was granted by King’s College London 
Ethics Committee (reference LRS-19/201–8210). Data for 
this study used proxy-reported children (aged 5–17 years), 
who could not give consent directly. Therefore, consent 
was from the proxy-reporting adult who was the app 
user, with governance granted to allow proxy-reported 
data usage in this circumstance. Full consent details, 
particularly pertaining to proxy-reported individuals, are 
provided in the appendix (p 1).
Procedures 
Data from all proxy-reported school-aged children 
(age 5–17 years) from all four countries of the UK 
were available from app launch to Feb 22, 2021 
(8 weeks after the UK peak SARS-CoV-2 positive speci-
men date). Data were analysed overall and within 
two age groups: younger children aged 5–11 years 
(UK primary school-aged children) and older children 
aged 12–17 years (UK secondary school-aged children, 
Research in context
Evidence before this study
COVID-19 in children is usually asymptomatic or manifests as a 
mild illness of short duration. Concerns have been raised 
regarding prolonged illness in children, with no clear resolution 
of symptoms several weeks after onset, as is observed in some 
adults. How common this might be in children, the clinical 
features of such prolonged illness in children, and how this 
might compare with illnesses from other respiratory viruses 
(and with general population prevalence of these symptoms) is 
unclear. A final database search was done in PubMed using the 
search terms ((‘‘COVID-19’’ OR ‘‘SARS-CoV-2’’) AND child*) on 
June 28, 2021.
Added value of this study
We provide a detailed description of the illness duration and 
symptom burden for COVID-19 in UK school-aged children (age 
5–17 years). Our data, collected in a digital surveillance platform 
through one of the largest UK citizen science epidemiological 
studies, show that long illness duration after SARS-CoV-2 
infection in school-aged children does occur, but is uncommon. 
Only a small proportion of children had illness duration beyond 
4 weeks, and their symptom burden decreased over time. 
Almost all children had symptom resolution by 8 weeks, 
providing reassurance about long-term outcomes. Additionally, 
the symptom burden in children with what has been termed 
long COVID-19 was not greater than that in children with long 
illnesses due to causes other than SARS-CoV-2 infection.
Implications of all the available evidence
Our data confirm that COVID-19 in UK school-aged children is 
usually of short duration and low symptom burden. Some 
children do have longer illness duration, and our findings validate 
their experiences; however, most of these children usually 
recover with time. Our findings emphasise that appropriate 
resources will be necessary for any child with prolonged illness, 
whether due to COVID-19 or other illnesses. Our study provides 
crucial data to inform discussions about the effect and 
implications of the pandemic on health-care resource allocation.
For the UK cases by specimen 
date see https://coronavirus.
data.gov.uk/details/cases
See Online for appendix
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noting that children can cease education from age 
16 years).
Children aged 16–17 years can register and report on 
the app independently, or be proxy-reported by an adult. 
However, as described in the appendix (p 2), only proxy-
reported 16-year-olds and 17-year-olds were included in 
this study.
Children were considered symptomatic of SARS-CoV-2 
if they were proxy-reported with relevant symptoms10,16 
between 1 week before and 2 weeks after infection 
confirmation (either PCR or lateral flow antigen test). 
Illness duration was calculated from the first symptom 
(having been previously asymptomatic) until recovery 
(return to asympto matic or, if proxy-reporting ceased 
before becoming asymptomatic, final proxy report). 
Individuals who were proxy-reported as asymptomatic 
but subsequently re-reported with symptoms within 
1 week of their last symptomatic report were considered 
unwell from initial presentation (ie, relapsing or remitting 
illness), with illness duration calculated accordingly. Data 
from children with reporting gaps longer than 1 week 
between symptomatic reports were excluded. Individual 
symptom prevalence and duration were assessed, with 
duration calculated from first to last report for that 
symptom.
Symptom burden was calculated as the number of 
different symptoms reported at least once over defined 
timeframes (during first week, first 28 days, from day 28 
until illness end, and entire illness duration).2 Illness with 
symptoms lasting for 28 days or more was termed LC28 
and for 56 days or more was termed LC56. Thus, by virtue 
of census dates, LC28 could be determined for children 
whose symptoms commenced on or before Jan 24, 2021, 
and LC56 for children whose symptoms commenced on 
or before Dec 29, 2020 (peak positive specimen date). 
Hospital presentation comprised emergency department 
presentation or hospital admission following symptom 
commencement. Proxy-reporting density was defined as 
the number of episodes of proxy-reporting over illness 
duration, and proxy-reporting persistence was defined as 
proxy-reporting until return to asymptomatic.
Several direct symptom questions were added to the 
app on Nov 4, 2020 (appendix pp 4–5), but these data 
were not included in the main illness profile analyses. 
Free-text reporting was possible across the entire 
period. Free-text data were divided into themes using 
descriptive word frequency, and items within themes 
were independently scrutinised by two clinicians 
(MAb, ELD) to ensure appropriateness. Individuals 
reporting symptoms within themes were then counted. 
Free-text data are reported as descriptive statistics and 
not included in illness profile analyses (appendix 
pp 6–8). Free-text data searching included neurological 
terms and symptoms potentially affecting attention, 
behaviour, learning or school performance or both; 
symptoms already assessed by direct questions were 
excluded.
Illness profiles, including illness duration and symptom 
burden, were also assessed in children testing negative 
for SARS-CoV-2, using a randomly selected control cohort 
(matched 1:1 for age, gender, and week of testing; 
appendix p 2), and compared with children who tested 
positive.
Prevalence data for common winter circulating viruses 
were obtained from national public health databases.14
Outcomes 
The primary outcome was illness duration and symptom 
burden in children who tested positive for SARS-CoV-2 
and in matched children who tested negative, assessed 
overall as well as for younger and older children.
Additionally, we assessed individual symptom prevalence 
and duration, hospital presentation, and the prevalence 
of prolonged illness duration.
Statistical analysis 
Data are presented using descriptive statistics. Due to 
rarity (some percentages <5%), CIs were calculated using 
Poisson distribution. Comparisons of data between 
groups were done using Wilcoxon signed-rank test, two-
tailed χ²-tests, or Fisher’s exact tests. We used Spearman 
correlation to assess correlation of illness duration with 
age. All analyses were done in Python version 3.7. 
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
Overall, 258 790 UK children aged 5–17 years 
were proxy-reported between March 24, 2020, and 
Feb 22, 2021. Posi tive SARS-CoV-2 testing was reported 
in 6975 children, of whom 1912 (666 younger and 
1246 older children) had a calculable illness duration 
and requisite proxy-report logging (figure 1). Because 
only 36 of these 1912 children had illness onset before 
Sept 1, 2020 (return-to-school), and given the limited 
testing access early in the UK pandemic,13 analyses 
were restricted to children with illness onset after 
Sept 1, 2020. 1734 (588 younger, 1146 older) children 
were proxy-logged on or before Jan 24, 2021, allowing 
LC28 to manifest.2 Similarly, 1379 (445 younger, 
934 older) children had symptoms commencing on or 
before Dec 29, 2020, allowing LC56 to manifest.2 Details 
regarding the final cohort are presented in the table, 
and additional demographic details (including ethnicity 
and index of multiple deprivation decile) are in the 
appendix (pp 9–10).
Median illness duration in children with COVID-19 
was 6 (IQR 3–11) days (table) and was shorter in 
younger than in older children (5, IQR 2–9 vs 7, 3–12) 
days, (p<0·0001). Age correlated with illness duration 
(Spearman’s rank-order rs 0·19, p<0·0001).
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1657 with duration <28 days
570 younger
1087 older
1734 with illness onset between Sept 1, 2020, 
and Jan 24, 2021
588 younger
1146 older




15 597 with illness onset between Sept 1, 2020, 
and Jan 24, 2021
8761 younger
6836 older
77 with duration ≥28 days
18 younger 
59 older
1719 with duration <28 days
585 younger
1134 older
15 with duration ≥28 days
3 younger 
12 older
13 863 not included in random matching 
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23 407 with regular logging
13 976  younger 
9431 older
1296 with irregular logging
857 younger
439 older
24 703 with duration calculable
14 833 younger
9870 older
68 554 with negative result
41 157 younger
27 397 older

























75 529 with valid test results 
44 454 younger
31 075 older
78 548 tested with PCR or lateral flow test
46 342 younger
32 206 older
3019 with invalid result
1888 younger
1131 older
258 790 UK children with details proxy-reported
154 061 younger children
104 729 older children
180 242 not tested with PCR or lateral flow test
107 719 younger 
72 523 older




1912 with regular logging
666 younger 
1246 older
1849 with irregular logging
662 younger
1187 older
3761 with duration calculable
1328 younger
2433 older
6975 with positive result
3297 younger
3678 older
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Individual symptom prevalence and duration are 
presented in figures 2 and 3, and the appendix (pp 11–13). 
The most common symptoms were headache (1079 
[62·2%] of 1734 children, of whom 324 [55·1%] of 588 
were younger and 755 [65·9%] of 1146 were older children) 
and fatigue (954 [55·0%] of 1734 children, of whom 
258 [43·9%] of 588 were younger and 696 [60·7%] of 1146 
were older children). The next most common symptoms 
in the 588 younger children were fever (257 children 
[43·7%]), sore throat (213 children [36·2%]), abdominal 
pain (163 children [27·7%]), and persistent cough 
(145 children [24·7%]). In the 1146 older children, the next 
most common symptoms were sore throat (585 children 
[51·0%]), anosmia (554 children [48·3%]), fever 
(396 children [34·6%]), and persistent cough (298 children 
[26·0%]). Overall, 1292 (74·5%) of 1734 children testing 
positive had fever, cough, anosmia, or a combination of 
these symptoms.
During the first week of illness, the median symptom 
burden was 3 symptoms (IQR 2–6) in the whole cohort 
(3 symptoms [2–5] in younger children and 4 symptoms 
[2–6] in older children). Symptom distrib ution by age 
group and gender is presented in the appendix 
(pp 12–13).
16 younger and 21 older children with COVID-19 
presented to hospital. The symptom profiles of these 
children were compared with community-managed 
children, but no statistical comparisons were undertaken, 
given the low number of hospital attendees (appendix 
p 18).
77 (4·4%, 95% CI 3·5–5·5) of 1734 children had LC28, 
including 18 younger and 59 older children. The median 
symptom burden in these children was 6 symptoms 
(IQR 4–8) during the first week of illness, and 
8 symptoms (6–9) over their entire illness. However, 
after day 28, the median symptom burden was low, at 
2 symptoms (IQR 1–4) in the cohort overall (3 symptoms 
[1–4] in younger children and 1 symptom [1–3] in older 
children). The most common symptoms experienced by 
these 77 children over their entire illness were fatigue 
(65 children [84·4%]), headache (60 children [77·9%]), 
anosmia (60 children [77·9%]), and sore throat 
(57 children [74·0%]). The symptom profile and pro-
gression over the first 28 days in children with LC28 is 
presented in figure 4. Headache, fatigue, and sore throat 
commonly manifest early in illness, with a persistence of 
fatigue and, to a lesser extent, headache. Anosmia often 
manifest only later in illness.
25 (1·8%, 95% CI 1·2–2·7) of 1379 children had LC56.2 
The median symptom burden in these children was 
6 symptoms (IQR 4–8) during the first week, and 
8 symptoms (6–10) over their entire illness. The most 
common symptoms in these 25 children over their entire 
illness were anosmia (21 children [84·0%]), headache 
(20 children [80·0%]), sore throat (20 children [80·0%]), 
and fatigue (19 children [76·0%]).
Children with positive SARS-CoV-2 test (n=1734) Children with negative SARS-CoV-2 
test (matched cohort, n=1734)
Younger group (aged 
5–11 years, n=588)








Females 301 (51·2%) 569 (49·7%) 565 (47·8%) 42 (54·5%) 870 (50·2%) 869 (50·1%)
Males 287 (48·8%) 577 (50·3%) 618 (52·2%) 35 (45·5%) 864 (49·8%) 865 (49·9%)
Age, years 9 (7–10) 15 (13–16) 13 (10–15) 14 (12–16) 13 (10–15) 13 (10–15)
Body-mass index (kg/m²) 17·0 (15·1–19·7) 20·1 (17·8–22·3) 19·0 (16·5–21·8) 18·6 (16·3–21·8) 19·2 (16·6–21·8) 19·0 (16·5–21·5)
Asthma 69 (11·7%) 147 (12·8%) 134 (11·3%) 10 (13·0%) 216 (12·5%) 229 (13·2%)
Heart disease 1 (0·2%) 1 (0·1%) 2 (0·2%) 0 2 (0·1%) 0
Diabetes 2 (0·3%) 5 (0·4%) 4 (0·3%) 0 7 (0·4%) 6 (0·3%)
Renal disease 0 2 (0·2%) 0 1 (1·3%) 2 (0·1%) 4 (0·2%)
Presentation to hospital 16 (2·7%) 21 (1·8%) 20 (1·7%) 1 (1·3%) 37 (2·1%) 26 (1·5%)
Illness duration, days 5 (2–9) 7 (3–12) 4 (2–6) 46 (32–58) 6 (3–11) 3 (2–7)
Number of symptoms in the first week 3 (2–5) 4 (2–6) 3 (2–5) 6 (4–8) 3 (2–6) 2 (1–4)
Data are n (%) or median (IQR). The cohort of children with positive SARS-CoV-2 testing is presented here both as younger and older groups, and for usual (ie, short) versus extended illness duration. Data refers 
to children with symptom onset between Sept 1, 2020, and Jan 24, 2021. Common paediatric comorbidities such as neurological or neurodisability disorders (eg, cerebral palsy) were not assessed. Presentation 
to hospital included presenting to the emergency department or admission to hospital. 
Table: Characteristics of school-aged children who tested positive for SARS-CoV-2, and the control cohort of children (matched 1:1 for age, gender, and week of testing) who tested 
negative for SARS-CoV-2
Figure 1: Study flowchart of inclusion and exclusion criteria
Overall number for the entire cohort of children is given first. Younger 
children=aged 5–11 years (UK primary school-aged children). Older 
children=aged 12–17 years (UK secondary school-aged children). Invalid 
result=PCR test or lateral flow test result proxy-reported as “failed test” or “still 
waiting”. Duration calculable=illness onset within defined timeframe of testing 
for SARS-CoV-2, and with defined endpoint. Regular logging=proxy-reporting at 
least once every 7 days during illness duration. Irregular logging=proxy-reporting 
with intervals of more than 7 days between proxy-reports during illness 
duration. Illness onset outside of study bounds=symptom onset before 
Sept 1, 2020, or after Jan 24, 2021. Presenting to hospital=either admitted to 
hospital or seen in the emergency department.
Articles
6 www.thelancet.com/child-adolescent   Published online August 3, 2021   https://doi.org/10.1016/S2352-4642(21)00198-X
Older children were more likely to manifest LC28 than 
were younger children (59 [5·1%] of 1146 older children 
vs 18 [3·1%] of 588 younger children; p=0·046). This 
observation was not evident in children with LC56 
(19 [2·0%] of 934 older children vs six [1·3%] of 
445 younger children; p=0·52).
Regarding symptom reporting from the additional app 
questions added on Nov 4, 2020 (with a smaller cohort 
due to a shorter time frame), the most common symptom 
was rhinorrhoea (198 [39·1%] of 507 younger children 
and 439 [47·1%] of 932 older children) and then sneezing 
(143 [28·2%] of 507 younger children and 269 [28·9%] of 
932 older children). These were also the most common 
symptoms observed in children with LC28 over their 
entire illness, with 33 (52·4%) of 63 children reporting 
each of rhinorrhoea and sneezing. 
Considering potential neurological symptoms other 
than headache and fatigue, dizziness was reported in 
84 (14·3%) of 588 younger children and 300 (26·2%) of 
1146 older children, with a median duration of 2 days 
(IQR 1–4) for younger children and 2 days (1–5) for older 
children. Confusion (including disorientation and drowsi-
ness) was reported in 15 (2·6%) of 588 younger children 
and 81 (7·1%) of 1146 older children, with a median 
duration 2 days (IQR 1–2) for younger children and 1 day 
(1–3) for older children. No statistical comparisons of 
these symptoms in children with shorter or longer illness 
duration were made, given their low prevalence in 
children with LC28 (figure 4).
Considering the questions added on Nov 4, 2020, the 
experience termed brain fog was reported for 30 (5·9%) of 
507 younger children and 105 (11·3%) of 932 older 
children, with a median duration of 1 day (IQR 1–4) for 
younger children and 2 days (1–5) for older children. Low 
mood was reported for 40 (7·9%) of 507 younger children 
and 145 (15·6%) of 932 older children, with a median 
duration of 2 days (IQR 1–3·5) for younger children and 
2 days (1–4) for older children (appendix p 17).
Free-text searching for specific neurological symptoms 
disclosed few reports of weakness (two children) or tics 
(one child). No severe neurological manifestations were 
reported (appendix pp 6–8). Irritability (three children, 
two irritable and one grumpy), emotional difficulties 
(two children, one with emotional difficulty and one with 
low mood), and behavioural difficulties (one child) were 
reported rarely; impaired attention and concen tration 
were not reported.
15 597 symptomatic children (including 8761 younger 
and 6836 older children) testing negative for SARS-CoV-2 
were proxy-reported at least once weekly within the study 
Figure 2: Prevalence of symptoms reported over the course of illness in 
younger (age 5–11 years, n=588) and older (age 12–17 years, n=1146) 
children testing positive for SARS-CoV-2
Data refers to children with symptom onset between Sept 1, 2020, 
and Jan 24, 2021.
0
Proportion of affected children (%)






















Figure 3: Median duration of each symptom and IQR in younger 
(age 5–11 years) and older (age 12–17 years) children
Data refers to children with symptom onset between Sept 1, 2020, 
and Jan 24, 2021. Black bars represent IQRs.
0
Number of symptomatic days
























www.thelancet.com/child-adolescent   Published online August 3, 2021   https://doi.org/10.1016/S2352-4642(21)00198-X 7
period and had calculable illness duration. Of these, 
1734 were matched to children testing positive (table; 
appendix pp 9–10). Their median illness duration was 
3 days (IQR 2–7) overall (3 days [2–7] for younger children 
and 4 days [2–7] for older children), shorter than for 
children testing positive (Wilcoxon test, p<0·0001)Indi-
vidual symptom duration and symptom prevalence are 
presented in the appendix (pp 14, 19). The most common 
symptoms over their entire illness were as follows: 
in the 588 younger children, sore throat (274 children 
[46·6%]), headache (228 children [38·8%]), fever 
(179 children [30·4%]), fatigue (158 children [26·9%]), 
and abdominal pain (145 children [24·7%]); in the 
1146 older children, sore throat (695 children [60·6%]), 
headache (559 children [48·8%]), fatigue (426 children 
[37·2%]), fever (234 children [20·4%]), and persistent 
cough (236 children [20·6%]). Overall, 805 (46·4%) of 
1734 children testing negative had fever, cough, anosmia, 
or a combination of these symptoms.
Few children testing negative had an illness duration 
of 28 days or more (15 of 1734 children, 0·9%, 95% CI 
0·5–1·4), which was lower than for children testing 
positive overall (p<0·0001) and within age groups (younger 
children, three [<1%] of 588 vs 18 [3·1%] of 588; p=0·0010; 
older children, 12 [1·0%] of 1146 vs 59 [5·1%] of 1146; 
p<0·0001). The symptom profile of these children over 
their first 28 days of illness is shown in the appendix (p 20). 
These children had a greater symptom burden than did 
children who tested positive for SARS-CoV-2 who had 
illness duration for 28 days or longer, both in the period 
beyond 28 days (5 symptoms [IQR 1·5–6·5] vs 2 symptoms 
[1–4]; p=0·0050; appendix p 22). and over their entire 
illness duration (9 symptoms [IQR 7·5–11] vs 8 symptoms 
[6–9]; p=0·025; appendix p 23).
Proxy-reporting was assiduous for all children. Proxy-
reporting density was higher in children testing negative 
for SARS-CoV-2 than for children testing positive 
(younger, 1·0, IQR 0·7–1·0 vs 0·9, 0·6–1·0; older, 
1·0, 0·7–1·0 vs 0·8, 0·6–1·0), noting the shorter illness 
duration in children testing negative. Proxy-reporting 
until asymptomatic (ie, perseverance) was higher in 
children testing negative than in children testing positive 
(1674 [96·5%] of 1734 vs 1551 [89·4%] of 1734; p<0·0001).
Among children testing positive, symptom logging 
ceased in 183 children before an asymptomatic report 
(22 with illness duration ≥28 days, 161 with duration 
<28 days). In the 77 children with illness duration of 
28 days or more, proxy-reporting continued until an 
asymptomatic report was received in 55 (71·4%). However, 
the remaining 22 children already had symptoms for at 
least 28 days and thus fulfil the definition of LC28. In 
children with illness duration of less than 28 days, an 
asymptomatic report was received for 90·3% (1496 of 1657). 
For the remaining 161 children, the median symptom 
burden at last report was 2 symptoms (IQR 1–3), and 
proxy-reporting usually ceased early in illness (in 11·3% of 
children with illness duration of <10 days, and 5·5% of 
children with illness duration of ≥10 days). Thus, we 
assumed that proxy-reporting cessation corresponded to 
illness resolution (ie, the child had recovered) and we 
calculated illness duration accordingly.
We considered the effect of this assumption. Excluding 
all children testing positive for whom a healthy report was 
not logged, the median illness duration in the remaining 
1551 children was unchanged (6 days, IQR 3–11 days) 
with LC28 prevalence of 3·5% (55 of 1551), within 
the previously calculated confidence interval of 3·5–5·5, 
using data from the entire cohort. Excluding only the 
161 children with assumed short-term symptoms, but 
including all children with LC28 (regardless of receipt 
of healthy report), LC28 prevalence was 4·9% (77 of 1573), 
again within the previously calculated confidence interval 
of 3·5–5·5. 
In children testing negative, logging ceased in 
60 children before a healthy report (four of 15 children 
with long illness duration and 56 of 1719 children with 
assumed short illness duration).
Discussion 
In this study, we show that symptomatic SARS-CoV-2 
infection in UK children aged 5–17 years is usually of 
short duration (6 days vs 11 days in adults2), with low 
symptom burden. Prolonged illness can occur but is 
infrequent (4·4% for LC28 and 1·8% for LC56) and lower 
than for adults (13·3% for LC 28 and 4·5% for LC56).2 
We found age to correlate with illness duration overall 
and in children with illness duration of 28 days or more, 
consistent with our previous findings in adults.2
The most common symptoms in our cohort of 
children with COVID-19 were headache (62·2%) and 
Figure 4: Heat maps showing symptom duration in school-aged children (age 5–17 years) testing positive for 
SARS-CoV-2 in whom at least one symptom persisted for at least 28 days
n=77. Colour bar provides a percentage comparison. Data refers to children with symptom onset between 
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fatigue (55·0%). A meta-analysis of studies that in-
cluded both community-based children and those ad-
mitted to hospital identified fever (47%) and cough (42%) 
as the most common symptoms in children with 
COVID-19; however, headache and fatigue were only 
assessed in half of the contributing cohorts.3 In our 
cohort, 37·7% reported fever and 25·5% reported a 
persistent cough. Anosmia and dysosmia were common 
(39·6%), which was higher than in a small study of 
adolescents with mild to moderate COVID-19 in which 
anosmia was reported in 24·1% of participants,17 noting 
that anosmia was a core symptom for testing access 
during our study period. Relevant to UK testing criteria, 
anosmia became more prevalent later in illness, at least 
in children with LC28.
In children with LC28, by day 28 the symptom burden 
was low (median 2 symptoms). Fatigue was proxy-
reported at some stage in most participants (84·4%). In 
our adult study, fatigue was almost universal in LC28 
(97·7% at some stage during illness);2 other adult studies 
have reported persistence of fatigue as 53·1% at 60 days18 
and 52·3% at 10 weeks.19
Few epidemiological studies provide normative data 
for headache and fatigue in children. Regarding head-
ache, a systematic review of population-based studies in 
individuals younger than 20 years reported that about 
60% were prone to headache;20 and 66% of children aged 
5–15 years reported headaches over the previous year.21 
Regarding fatigue, a study of 2936 children found that 
4·4% had “more than a few days of disabling fatigue”.22 
In one study, prevalence of chronic fatigue syndrome 
(here defined as “disabling fatigue lasting more than 
3 months…with no other cause”) was 1% in children 
aged 11–16 years;23 and in the Avon Longitudinal Study 
prevalence of “chronic disabling fatigue” (here defined 
as ‘‘fatigue lasting more than 6 months and associated 
with absence from full-time school or had prevented...
activities’’) was 1·5% in children aged 13 years 
and 2·2% in children aged 16 years.24 Considering 
fatigue after viral infection, median illness duration after 
Epstein–Barr virus infection in symptomatic university 
students was 10 days, with a median duration of fatigue 
of 15·5 days.25 
Being able to contextualise COVID-19 in children 
is complicated by a lack of contemporaneous data 
on illness profiles after other viral infections. A study 
of 242 158 children and adolescents with COVID-19 
(9769 admitted to hospital) and 2 084 180 children with 
influenza during 2017–19 (numbers admitted to hos-
pital unclear) suggested that dyspnoea, anosmia, and 
gastrointestinal tract symptoms were more common 
with COVID-19 than with influenza.26 However, symp-
toms were only reported as present or absent at 30 days 
in both groups, preventing more granular comparisons.
A strength of our study is its comparison of contem-
poraneous illness profiles of symptomatic children 
testing positive versus negative for SARS-CoV-2. Children 
testing positive had longer median illness duration 
(6 days vs 3 days) and were more likely to have illness 
duration of at least 28 days (4·4% vs 0·9%). However, 
some children testing negative also had illness duration 
of at least 28 days; these children had higher symptom 
counts over their entire illness duration and at day 28, 
acknowledging our small sample size. We considered 
whether some of these children might have false-negative 
results. However, there is no evidence that the sensitivity 
and specificity of SARS-CoV-2 testing differ in children 
compared with adults, with sensitivity for PCR tests 
for SARS-CoV-2 of about 95%. The symptom profiles 
of children testing positive and negative suggest some 
differences, although these were not statistically assessed. 
Notably, the prevalence of non-SARS-CoV-2 respiratory 
viruses (influenza A, influenza B, parainfluenza, adeno-
virus, and respiratory syncytial virus) were unusually 
low over the 2020–21 winter in the UK,14,27,28 except for 
the rhinovirus peak commonly observed in September 
(return-to-school).14 With the relaxation of social dis-
tancing in the UK, these illnesses might return towards 
their usual higher prevalences. Our data emphasise 
that other childhood illnesses might also have pro-
tracted burdensome courses, requiring consideration in 
post-pandemic service planning.
Short-term and long-term effects of COVID-19 on 
school performance and learning have been a matter of 
concern.11 In our cohort, attentional problems, memory 
complaints, and anxiety were not reported, and cases of 
low mood and irritability were consistent with previous 
school-aged population data. Our data do not support 
anecdotal reports of weakness and seizures as being 
common in children with COVID-19 of any duration, 
and no severe neurological symptoms were reported. 
However, any persistent illness can have adverse mental 
health outcomes and affect school attendance.29 Mental 
health data could not be proxy-reported, limiting our 
ability to assess mental health comprehensively in 
children during the pandemic, and we did not collect 
data regarding school attendance.
In considering other data sources, the UK Office 
for National Statistics (ONS) did SARS-CoV-2 testing 
irrespective of symptoms from Dec 2 to Dec 10, 2020, 
in 7089 pupils drawn from 121 schools (41 primary, 
80 secondary); 0·94% of pupils and 0·99% of staff in 
primary schools tested positive, and 1·22% of pupils and 
1·64% of staff in secondary schools. However, ONS have 
warned that their conclusions might not have general 
validity, because there was deliberate oversampling of 
schools with higher infection rates early after return-to-
school. Moreover, these figures do not capture fluctu ations 
as the pandemic progressed. In our integrated data across 
the pandemic, 6975 (2·7%) of 258 790 proxy-reported 
children tested positive. It should be noted that PCR 
testing was only available for symptomatic individuals 
(and rarely during the first wave); and proxy-reporting was 
voluntary and through the COVID Symptom Study app 
For more on testing specificity 
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with its 4·6 million adult user base over-representative of 
women, those of White background, and those with above-
average socio economic status12 compared with the general 
UK popu lation. Furthermore, we cannot characterise 
regional variability because geographic information was 
un available for many participants. These issues might 
cause selection bias in our study.
Reporting of SARS-CoV-2 data is not uniform across 
the UK: the four countries report data for children and 
young people within differing timeframes and age groups 
(appendix p 15). Conser vatively, our study represents 
about 1–2% of UK school-aged children testing positive 
during the pandemic.
The most recent ONS data (released April, 2021) 
estimated that 9·8% of children aged 2–11 years 
and 13·0% of children aged 12–16 years had ongoing 
symptoms 5 weeks after testing positive, with 7·4% of 
those aged 2–11 years and 8·2% of those aged 12–16 years 
still reporting symptoms at 12 weeks.30 These figures 
decreased compared with previous ONS estimates in 
January, 2021 (eg, from 12·9% to 9·8% in children aged 
2–11 years).30,31 The ONS reported a control group (never 
symptomatic, never tested, never self-isolated, and never 
a contact of anyone testing positive) with baseline pooled 
symptom rates of 2% in children aged 2–11 years and 
1·7% in children aged 12–16 years.30,31 There is limited 
published detail of ONS methodology.
The contrast between our LC28 prevalence and ONS 
figures might result from ONS requiring two consecutive 
asymptomatic visits to define illness end; thus, children 
with asymptomatic periods of more than 1 week between 
symptoms would be captured by ONS but not by the 
present study. Notably, ONS’s sensitivity analysis of 
the effect of defining illness end to a single asymptomatic 
visit markedly lowered their prevalence estimates, 
especially for illness of more than 12 weeks (from 13·7% 
to 0·9%30), which is more consistent with our results. 
Additionally, ONS estimates are made using current and 
recalled data collected in the first week of each month, 
whereas our app-based data are collected in real-time. 
Our data concord with a small Australian study reporting 
follow-up of 151 children with SARS-CoV-2 (median 
age 3 years): 12 had symptoms 3–8 weeks after initial 
presentation (most commonly cough or fatigue, or both), 
and all returned to baseline health by 3–6 months.32
Our study is one of the largest UK citizen-collaborative 
epidemiological studies.2,15 Our census points allowed 
capturing of all children with illness duration of at least 
8 weeks who presented before the UK peak positive 
specimen date. By ensuring that symptoms concorded 
with testing, we could attribute symptoms to SARS-
CoV-2 infection defined by contemporaneous test 
results. We avoided bias from limited test availability 
early in the pandemic by restricting analyses from 
Sept 1, 2020, but we acknowledge there were still some 
access issues.33 Specifically, to be eligible for PCR testing, 
individuals were required to have fever, cough, anosmia, 
or a combination of these symptoms, criteria that were 
largely informed by adult symptomatology, which might 
miss some paediatric manifestations of COVID-19 (eg, 
abdominal pain3, reported in 27·8% of our younger 
children). Free-text data did not suggest common symp-
toms unique to children; qualitative analysis was not 
undertaken given its ad hoc collection and potential bias 
from additional direct questions after Nov 4, 2020 (ie, 
once directly asked, a symptom was unlikely to be free-
text reported). Additionally, we did not ask specifically 
about MIS-C. Only 74·5% of children testing positive 
and 46·4% of children testing negative were reported to 
have fever, cough, anosmia, or a combination of these 
symptoms. We do not know why the remaining children 
were tested. The positive predictive value of any symp-
tom varies according to illness prevalence, and here is 
clearly subject to the pandemic dynamics.34 However, 
nearly a quarter of symptomatic children testing positive 
for SARS-CoV-2 during the UK’s second wave did 
not report any of these symptoms, suggesting that UK 
testing policy needs reconsideration.
We also acknowledge that symptoms were proxy-
reported rather than directly ascertained. This is common 
in clinical assessment of children, particularly younger 
children. We do not have linkage to general practice or 
hospital records to validate proxy-reported data. Crucially, 
proxy-reported children depended upon an adult with 
access and capacity to participate in the COVID Symptom 
Study.10 Socioeconomic demographics of our study’s 
participants, along with UK general population data, are 
presented in the appendix (pp 9–10); beyond this we 
cannot comment on the characteristics of proxy-reported 
versus non-reported children. We did not have information 
on the relationship of the contributor to the proxy-reported 
child, which could influence reporting. For example, 
an unwell contributor might be too ill to proxy-report for 
a child; however, our high proxy-reporting density and 
perseverance of all symptomatic children suggest that 
this was uncommon. Current or previous symptoms 
experienced by contributors might also influence their 
proxy-reporting.
Our national study provides the first detailed description 
of COVID-19 in symptomatic school-aged children. 
Although uncommon, a small proportion of children have 
prolonged illness duration and persistent symptoms. Our 
LC56 data provide reassurance regarding their long-term 
outcomes. The symptom burden in children testing 
negative for SARS-CoV-2 but with long illness duration 
emphasises that allocation of appropriate resources will be 
necessary for any child with prolonged illness, whether 
from SARS-CoV-2 infection or other illness. Our study 
provides timely and crucial data about the effect and 
implications of the pandemic on UK paediatric health-care 
resource allocation.
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